NCCM
AVDL

Nine Chapters Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Nine Chapters Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$132K Buy
+12,600
New +$120K 0.29% 115

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Nine Chapters Capital Management's AVDL Position: Q3 2017 in Review

Nine Chapters Capital Management opened a new position in Avadel Pharmaceuticals (AVDL) in Q3 2017: 12,600 shares worth $132K. The stake represents 0.29% of the portfolio and ranks #115 among its holdings.

82 funds tracked by Wall St. Rank hold AVDL as of Q3 2017.

  • Nine Chapters Capital Management held 12,600 shares of Avadel Pharmaceuticals worth $132K as of Q3 2017.
  • Avadel Pharmaceuticals was a new Nine Chapters Capital Management position in Q3 2017.
  • Avadel Pharmaceuticals made up 0.29% of Nine Chapters Capital Management's portfolio in Q3 2017, its #115 holding.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.